Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU

• Published in: Critical care explorations 2022-11, Vol.4 (11), p.e0785-e0785
• Main Authors: Fetters, Megan B., Diep, Calvin, Ran, Ran, Kloosterboer, Amy
• Format: Article
• Language: English
• Subjects: Brief Report
• ISSN: 2639-8028; 2639-8028
• DOI: 10.1097/CCE.0000000000000785

Describe the efficacy and safety of guanfacine for dexmedetomidine weaning in critically ill patients. DESIGNRetrospective descriptive analysis. SETTINGSix hundred thirteen-bed academic medical center from October 2020 to October 2021. PATIENT/SUBJECTSAll Adult patients on IV dexmedetomidine who received at least one dose of guanfacine for sedation or agitation were included. INTERVENTIONSEnteral guanfacine. MEASUREMENTS AND MAIN RESULTSThe primary outcome was discontinuation of dexmedetomidine therapy within 48 hours after guanfacine initiation. Secondary outcomes assessed included adjunctive medication use, rate of dexmedetomidine reinitiation, and safety outcomes. One hundred five patients were included in the analysis. Median age was 59 years old, 66% were male, and median daily dose of guanfacine was 1.5 mg. Dexmedetomidine was discontinued within 48 hours in 58% of patients (n = 61) and within 72 hours in 71% of patients (n = 75). Fifty-five percent of patients (n = 58) required rescue medications for poorly controlled agitation, sedation, or pain while on guanfacine. Dexmedetomidine withdrawal occurred in 2% of patients (n = 2) while on guanfacine. Adverse effects attributed to guanfacine occurred in 8% of patients (n = 8), all experiencing hypotension leading to medication discontinuation. CONCLUSIONDexmedetomidine was successfully weaned within 48 hours of guanfacine initiation in 58% of patients with minimal withdrawal or adverse effects. Guanfacine may be an effective and safe enteral option for dexmedetomidine weaning in critically ill patients.